Researchers based at Uppsala University in Sweden have created an adeno-associated viral (AAV) vector treatment for glioma or glioblastoma that extended survival in a mouse model of the brain cancer. Writing in the May 11, 2023, issue of Cancer Cell, the researchers reported that by introducing an inflammatory protein known as LIGHT to the tumor microenvironment using the AAV treatment, the mice were better able to fight the cancer. Read More
An experimental antibiotic was able to prevent recurrent Clostridioides difficile infections (rCDI) by killing bacterial spores as well as growing spores. Researchers from the University of Notre Dame reported their findings in the Proceedings of the National Academy of Sciences on May 8, 2023. Read More
Inflammatory bowel disease (IBD) is a chronic, immunologically mediated disorder of the gastrointestinal tract in which tissue damage and sustained inflammation lead to long-term dysfunction of the gastrointestinal tract. Read More
Angelini Pharma SpA and JCR Pharmaceuticals Co. Ltd. have entered into an exclusive global development and commercialization agreement for the development of novel biologic therapies that applies J-Brain Cargo blood-brain barrier penetrating technology for the treatment of epilepsy, applying undisclosed effectors. Read More
A recent Glaxosmithlline Intellectual Property (No 4) Ltd. and Ideaya Biosciences Inc. patent describes the development of thiadiazolyl derivatives acting as DNA polymerase θ (POLQ) inhibitors reported to be useful for the treatment of cancer. Read More
Cancer immunotherapy candidate BSI-508, a bispecific fusion molecule targeting PD-1 and CD47, is undergoing early development at Biosion Inc., who recently presented preclinical data on the product. Read More
It is known that the Hippo/YAP signaling pathway plays a crucial role in cell proliferation and tumorigenesis; is thought to contribute to 10% of all cancer types. TYK Medicines Inc. has presented a novel YAP/TEAD interaction inhibitor compound, TY-1054, as a potential approach for treating cancer with dysregulated Hippo/YAP pathway. Read More
Research at Pathios Therapeutics Ltd. has led to the identification of tricyclic psychosine receptor (GPR65) antagonists reported to be useful for the treatment of cancer, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease and autoimmune diseases. Read More
Pharma Mar SA has developed new microtubule destabilizers (tubulin polymerization inhibitors) reported to be useful for the treatment of cancer. Read More
Researchers from Etern Biopharma (Shanghai) Co. Ltd. recently reported the discovery and preclinical characterization of ETS-003, a novel YAP/TAZ-TEAD protein-protein interaction (PPI) inhibitor, being developed for the treatment of cancer. Read More
